XML 42 R19.htm IDEA: XBRL DOCUMENT
v3.22.1

STOCK-BASED COMPENSATION | 9 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2021 | Mar. 31, 2021
Equity [Abstract] |  |
STOCK-BASED COMPENSATION | NOTE 6 – STOCKHOLDERS’ DEFICIT AND STOCK-BASED COMPENSATION During the three months ended December 31, 2021, the Company sold 30,865 shares of common stock to its chief executive officer and its chairman of the board of directors, president, chief financial officer and treasurer, issued 8,334 shares of common stock to a service provider and issued 5,775 shares to its non-employee directors under the Company’s outside director compensation plan. At December 31, 2021, the Company had an obligation to issue 16,666 shares of common stock to service providers, and the value of these shares was recorded as common stock issuable in the condensed consolidated balance sheet. Amended 2017 Equity Incentive Plan In October 2017, the Company’s board of directors (the Board) approved the 2017 Equity Incentive Plan (the Plan) with 1,000,000 shares of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance under the Plan by 333,334 and 1,333,334 shares, respectively. Under the Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board. Stock-Based Compensation Expense The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant date fair value. The unamortized compensation cost, as of December 31, 2021, was $7,419,022 related to stock options and is expected to be recognized as expense over a weighted-average period of approximately two years. During the nine months ended December 31, 2021, the Company granted options to purchase 723,269 shares of its common stock to employees, directors and consultants. The options had 10-year terms, and 85,484 options vested immediately when granted. The fair value of the options was determined to be $8,108,043 of which $1,769,805 was recorded as stock-based compensation expense and included in the condensed consolidated statement of operations for the nine months ended December 31, 2021. The following assumptions were used in the fair value method calculations: Schedule of Fair Value Assumptions
|  | Three Months Ended December 31, |  |  | Nine Months Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Risk-free interest rates |  |  | 1.26% - 1.36% |  |  |  | 0.38% |  |  |  | 0.8% - 1.36% |  |  |  | 0.28% - 0.38% |
Volatility |  |  | 197% - 253% |  |  |  | 87% |  |  |  | 89% - 370% |  |  |  | 87% - 127% |
Expected life (years) |  |  | 5.0 – 6.0 |  |  |  | 5.2 – 5.7 |  |  |  | 5.0 - 6.2 |  |  |  | 5.0 - 6.0 |
Dividend yield |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur. A summary of stock option activity under the Plan is presented below: Schedule of Stock Option activity
|  |  |  |  | Options Outstanding |
|  | Shares Available for Grant |  |  | Number of Shares |  |  | Weighted Average Exercise Prices |
Balance at March 31, 2021 |  |  | 136,082 |  |  |  | 1,197,252 |  |  | $ | 5.25 |
Options granted |  |  | (60,774 | ) |  |  | 60,774 |  |  |  | 12.69 |
Share awards |  |  | (1,836 | ) |  |  | — |  |  |  | — |
Options cancelled and returned to the Plan |  |  | 7,547 |  |  |  | (7,547 | ) |  |  | 8.61 |
Balance at June 30, 2021 |  |  | 81,089 |  |  |  | 1,250,479 |  |  |  | 5.58 |
Additional shares authorized under the Plan |  |  | 1,333,334 |  |  |  | — |  |  |  | — |
Options granted |  |  | (396,384 | ) |  |  | 396,384 |  |  |  | 12.15 |
Share awards |  |  | (3,636 | ) |  |  | — |  |  |  | — |
Options cancelled and returned to the Plan |  |  | 49,213 |  |  |  | (49,213 | ) |  |  | 7.02 |
Balance at September 30, 2021 |  |  | 1,063,546 |  |  |  | 1,597,650 |  |  |  | 7.17 |
Options granted |  |  | (266,112 | ) |  |  | 259,559 |  |  |  | 9.99 |
Share awards |  |  | (5,775 | ) |  |  | — |  |  |  |  |
Options cancelled and returned to the Plan |  |  | 29,073 |  |  |  | (11,256 | ) |  |  | 7.24 |
Balance at December 31, 2021 |  |  | 820,732 |  |  |  | 1,845,953 |  |  |  | 7.57 |
There were no stock options exercised during the nine months ended December 31, 2021 and 2020. The following table summarizes the range of outstanding and exercisable options as of December 31, 2021: Schedule of Outstanding and Exercisable Option, Range
|  | Options Outstanding |  |  | Options Exercisable |
Range of Exercise Price |  | Number Outstanding |  |  | Weighted Average Remaining Contractual Life (in Years) |  |  | Weighted Average Exercise Price |  |  | Number Exercisable |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic value |
$1.98 - $17.70 |  |  | 1,845,953 |  |  |  | 8.13 |  |  | $ | 7.57 |  |  |  | 1,011,586 |  |  | $ | 5.10 |  |  | $ | 3,564,268 |
The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option at December 31, 2021. The Company is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise of stock options as financing cash flows in the consolidated statements of cash flows. For the nine months ended December 31, 2021 and 2020, there were no such tax benefits associated with the exercise of stock options. | NOTE 5 – STOCK-BASED COMPENSATION Equity Compensation Plan In October 2017, the Company’s board of directors (the Board) approved the 2017 Equity Incentive Plan (the 2017 Plan) with 3,000,000 shares of common stock reserved for issuance. In January 2020, the Board approved an amendment to the 2017 Plan to increase the number of shares reserved for issuance by 1,000,000 shares. Under the 2017 Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units. The 2017 Plan is administered by the Board or, in the alternative, a committee designated by the Board. The exercise or purchase price of a stock option shall be calculated as follows:
| (i) | In the case of an incentive stock option, (a) granted to employees, who, at the time of the grant of such incentive stock option own stock representing more than 10% of the voting power of all classes of stock of the Company, the per share exercise price shall be not less than 110% of the fair market value per share on the date of grant; or (b) granted to employees, other than to employees, described in the preceding clause, the per share exercise price shall be not less than 100% of the fair market value per share on the date of grant;
| (ii) | In the case of a non-qualified stock option, the per share exercise price shall be not less than 100% of the fair market value per share on the date of grant unless otherwise determined by the Board; and
| (iii) | In the case of other grants, such price as determined by the Board.
The Board is responsible for determining the consideration to be paid for the shares of common stock to be issued upon exercise or purchase. The 2017 Plan generally does not allow for the transfer of awards, and the Board may amend, suspend or terminate the 2017 Plan at any time. Stock-Based Compensation Expense The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant date fair value. The unamortized compensation cost, as of March 31, 2021 was $2,242,352 related to stock options and is expected to be recognized as expense over a weighted-average period of approximately 2 years. During the year ended March 31, 2021, options granted to purchase shares of its common stock to employees, directors and consultants had 10-year terms and a grant-date fair value of $1,101,737. Options to purchase 10,476 shares vested immediately on the respective grant dates. The following assumptions were used in the fair-value method calculations:
|  | Year ended March 31, |
|  | 2021 |  | 2020 |
Risk-free interest rates |  |  | 0.28% - 0.71% |  |  | 0.77% - 2.37% |
Volatility |  |  | 87% - 127% |  |  | 86% - 103% |
Expected life (years) |  |  | 5.0 - 6.0 |  |  | 5.0 - 6.0 |
Dividend yield |  |  | —% |  |  | —% |
The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur. A summary of stock option activity under the 2017 Plan is presented below:
|  | Shares |  |  | Options Outstanding |
|  | Available |  |  | Number of |  |  | Weighted Average |
|  | for Grant |  |  | Shares |  |  | Exercise Price |
Balance at March 31, 2019 |  |  | 490,031 |  |  |  | 509,969 |  |  |  | 2.56 |
Additional shares authorized under the Plan |  |  | 333,334 |  |  |  | — |  |  |  | — |
Options granted |  |  | (572,402 | ) |  |  | 572,402 |  |  |  | 6.75 |
Options cancelled and returned to the Plan |  |  | 23,056 |  |  |  | (23,056 | ) |  |  | 6.75 |
Balance at March 31, 2020 |  |  | 274,019 |  |  |  | 1,059,315 |  |  |  | 4.74 |
Options granted |  |  | (163,492 | ) |  |  | 163,492 |  |  |  | 8.64 |
Options cancelled and returned to the Plan |  |  | 25,555 |  |  |  | (25,555 | ) |  |  | 6.75 |
Balance at March 31, 2021 |  |  | 136,082 |  |  |  | 1,197,252 |  |  |  | 5.25 |
There were no stock options exercised during the years ended March 31, 2021 and 2020. The following table summarizes the range of outstanding and exercisable options as of March 31, 2021:
|  | Options Outstanding |  |  | Options Exercisable |
Range of Exercise Price |  | Number Outstanding |  |  | Weighted Average Remaining Contractual Life (in Years) |  |  | Weighted Average Exercise Price |  |  | Number Exercisable |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic value |
$1.98 - $9.48 |  |  | 1,197,252 |  |  |  | 8.25 |  |  | $ | 5.25 |  |  |  | 742,913 |  |  | $ | 3.96 |  |  | $ | 8,763,260 |
The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option. The Company is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise of stock options as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2021 and 2020, there were no such tax benefits associated with the exercise of stock options.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration